Japan's public health insurance system is set to cover genomic testing for cancer patients who have not responded to conventional cancer treatments from 1 June onwards, reported The Japan Times citing a recent decision made by the health ministry. Under the new inclusion, patients will only have to pay 10-30% of testing fees.